Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and business related to providing data and information; develops and sells foothold; and research and development of mucosal vaccines. In addition, the company provides contract support services for experimental research; contract testing of agricultural production materials; solutions for education and healthcare, system development, human resource development, and training business; marketing support services; and IT services for medical and healthcare-related issues. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Kita, Japan.
Shionogi Pharmaceutical revised upward its FY2026 (ending March 2026) final dividend forecast by ¥5 per share to ¥38, re…
Summary
Shionogi Pharmaceutical revised upward its FY2026 (ending March 2026) final dividend forecast by ¥5 per share to ¥38, resulting in an annual dividend of ¥71 per share (¥10 increase YoY). This marks the 14th consecutive year of dividend increases, driven by strong execution of the HIV business (LAI formulations generating robust royalties and dividends from ViiV Healthcare), successful domestic M&A integration, and solid performance in infectious disease and QOL therapeutic areas. The company targets a dividend-on-equity (DOE) of 4%+ as part of its STS2030 Revision medium-term plan.
BANK OF CHINA (HONG KONG) LIMITED-PING AN LIFE INSURANCE COMPANY OF CHINA, LIMITEDBANK OF CHINA (HONG KONG) LIMITED-PING AN LIFE INSURANCE COMPANY OF CHINA, LIMITED（常任代理人：シティバンク、エヌ・エイ東京支店）
19,068
2.21%
7
STATE STREET BANK WEST CLIENT - TREATYSTATE STREET BANK WEST CLIENT - TREATY 505234（常任代理人：株式会社みずほ銀行決済営業部）
18,474
2.14%
8
State Street Bank and Trust CompanySTATE STREET BANK AND TRUST COMPANY 505001（常任代理人：株式会社みずほ銀行決済営業部）
12,083
1.40%
9
JP MORGAN CHASE BANKJP MORGAN CHASE BANK 385781（常任代理人：株式会社みずほ銀行決済営業部）
10,983
1.27%
10
State Street Bank and Trust CompanySTATE STREET BANK AND TRUST COMPANY 505103 （常任代理人：株式会社みずほ銀行決済営業部）